Key result
Remote hemodynamic monitoring with implantable devices, particularly the CardioMEMS pulmonary artery pressure sensor, has been shown to reduce heart failure hospitalizations.
Why the study?
Heart failure remains a substantial burden with rising incidence and limited efficacy of standard management strategies in reducing hospitalizations and mortality, warranting remote hemodynamic monitoring with implantable devices.
Does remote hemodynamic monitoring with implantable devices reduce heart failure hospitalizations and mortality in patients with heart failure?
Does remote hemodynamic monitoring with implantable devices reduce heart failure hospitalizations and mortality in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Remote hemodynamic monitoring using pulmonary artery pressure sensors effectively reduces heart failure hospitalizations, whereas current diagnostic algorithms in standard defibrillators have not consistently shown similar benefits.
Heart failure remains a substantial socioeconomic burden to our health care system. With the aging of the population, the incidence is expected to rise in the ensuing years. Standard heart failure management strategies have failed to reduce hospitalizations and mortality. In patients with heart failure, remote hemodynamic monitoring with implantable devices provides essential data, which can be used in unison with standard patient management to reduce heart failure hospitalizations. This review will chronicle the important clinical trials of various implantable devices and describe the emerging technologies in remote heart failure management. Cardiovascular implantable electronic devices, namely implanted cardioverter-defibrillator and cardiac resynchronization therapy devices with defibrillator, have evolved beyond sole resynchronization and currently can deliver real-time cardiac hemodynamics. Clinical data regarding hemodynamic monitoring with implanted cardioverter-defibrillator and cardiac resynchronization therapy devices with defibrillator have not consistently demonstrated a reduction in heart failure or mortality benefit. However, there is promise in the future with the application of multiparameter diagnostic algorithms with these devices. The most efficacious implantable device has been the pulmonary artery pressure sensor, CardioMEMS. This device has been proven to be safe and shown to reduce heart failure hospitalizations. Moreover, multiple newly developed devices are currently under investigation after successful first-in-man studies.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Heart failure. Implantable cardiovascular devices for remote hemodynamic monitoring was evaluated. Remote hemodynamic monitoring with implantable devices, particularly the CardioMEMS pulmonary artery pressure sensor, has been shown to reduce heart failure hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: